Vivani Medical Inc (VANI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.49+7.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Vivani aims to release SLIM-1 results by end of 2026. It plans Phase 1 results for NPM-139 also by year-end. Operating losses are improving slightly, from -$7.46M to -$6.82M in early 2026. The company has strong patents and targets big health problems.
Vivani is still losing money and not growing revenue. Analysts expect EPS losses to deepen to -$0.53 by 2027. The company has no clear revenue or profit guidance. Its turnaround progress is slow and uncertain.
The market values Vivani at about $0.30 per share, reflecting high risk. Our fair value matches this low price. The market expects large losses to continue and no revenue growth soon. We see some hope in product milestones but no clear earnings turnaround yet.
Breaks if: NPM-139 Phase 1 results delayed beyond 2026-12-31
Breaks if: Operating loss worsens beyond -$7.5M in 2026-Q1
SLIM-1 results delayed beyond 2026-12-31
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. VANI is currently navigating through a challenging phase with fragile earnings and high operational losses, while also being influenced by broader healthcare sector trends.
The market seems to have priced in a level of fragility due to VANI's expensive valuation, which does not fully reflect the underlying risks. There is an expectation that the company will manage its losses and maintain its cash runway effectively.
Management is focused on key priorities, such as releasing clinical trial results and advancing partnerships, which could support future growth. However, the company is still facing high operational losses, and its recent financial performance has been below industry peers.
The long-term thesis hinges on the outcomes of upcoming clinical trials and the performance of sector peers. Additionally, any cuts to guidance or worsening economic conditions could negatively impact VANI's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Vivani aims to release top-line SLIM-1 results by the end of 2026.
In the next 1 to 3 years, VANI's performance will depend heavily on its ability to execute on management priorities and navigate sector dynamics. Not investment advice.